Clinical Trial

Grape Polyphenols for Prevention of Chemotherapy-Induced Cardiotoxicity

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 19, 2026 (before its estimated May 9, 2026 completion). Its status may not reflect the trial's current state.
Summary
This pilot randomized clinical study aims to evaluate the cardioprotective effects of a grape polyphenol concentrate in patients receiving anthracycline- and/or trastuzumab-based chemotherapy. Adult patients at high or very high risk of chemotherapy-induced cardiotoxicity will be randomized to receive either a grape polyphenol concentrate or placebo for three months, starting with chemotherapy. Cardiac function and cardiotoxicity will be assessed using echocardiographic parameters and circulating biomarkers at baseline, 3 months, and 6 months.
Trial Details
NCT Number NCT07419711
Lead Sponsor Nazarbayev University
Conditions Chemotherapy-induced Cardiotoxicity, Breast Cancer
Enrollment 120 participants
Start Date 2026-02-09
Primary Completion 2026-05-09 (estimated)
Study Completion 2027-11-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-19